Company Monitoring Page for Arqule

latest headlines for company on cafepharma

Merck wraps up $2.7bn acquisition of biopharmaceutical firm ArQule
Pharmaceutical Business Review
Fri, 01/17/20 - 11:13 am
Tags:
Merck, Arqule, M&A
Why Biotech Stock ArQule Soared 108% in December
Motley Fool
Sat, 01/4/20 - 07:27 pm
Tags:
Merck, Arqule, M&A
Merck to acquire ArQule for $20 per share in cash or about $2.7 billion
Marketwatch
Mon, 12/9/19 - 10:06 am
Tags:
Merck, M&A, Arqule, oncology
3 Soaring Biotech Stocks to Watch in December
Motley Fool
Mon, 12/2/19 - 10:40 am
Tags:
Arrowhead Pharmaceuticals, RNAi, Adverum Biotechnologies, gene therapy, ADVM-022, Arqule, ARQ-531
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Sun, 10/27/19 - 10:55 pm
Tags:
Adamis Pharmaceuticals, Redhill Biopharma, Amag Pharmaceuticals, Arqule, Agile Therapeutics, Agios Pharmaceuticals, Deciphera, Mirati Therapeutics, Sutro BioPharma, Merck, Pfizer, Amgen, EXACT Sciences, Bristol-Myers Squibb, Celgene, Oyster Point Pharma
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/16/19 - 05:41 pm
Tags:
FDA, Merck, Arqule, Affimed, BeiGene, Epizyme, MorphoSys, Theravance, Allena Pharma, Akero Therapeutics, Atreca, Dermavant Sciences, Personalis, Prevail Therapeutics, Stoke Therapeutics, IPOs
EHA 2019 – turnaround puts Arqule in the takeover frame
EP Vantage
Sat, 06/15/19 - 05:47 pm
Tags:
Arqule, ARQ 531, EHA, Btk inhibitors
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
Sun, 06/9/19 - 01:36 pm
Tags:
ADA, Merck, Keytruda, NGM Biopharmaceuticals, NGM313/MK-3655, Corbus Pharmaceuticals, Nektar, Galapagos, Kezar Life Sciences, Kura Oncology, Bluebird Bio, BeiGene, Global Blood Therapeutics, Blueprint Medicines, Regeneron, Arqule, Sunesis, Sutro BioPharma, Incyte, Geron, Forty Seven
Imbruvica resistance provides early but fertile development ground
EP Vantage
Fri, 03/15/19 - 10:43 am
Tags:
Arqule, Imbruvica, drug development, Btk inhibitors
Basilea Enters Collaboration With Roche to Study BAL087 in Combination With Tecentriq in Urothelial Cancer
CP WIre
Thu, 01/24/19 - 11:43 am
Tags:
Arqule, Basilea, Roche, BAL087, urothelial cancer, Tecentriq
Thu, 01/24/19 - 10:38 am
Tags:
Arqule, Basilea, Roche, BAL087, urothelial cancer, Tecentriq
The 4 Best Biotech Stocks of 2018 (So Far)
Motley Fool
Sat, 07/14/18 - 01:22 pm
Tags:
biotech, Arrowhead Research, Endocyte, Arqule, Madrigal Pharmaceuticals
4 Biotech Stocks That Tripled in the First Half of 2018
Motley Fool
Mon, 07/2/18 - 10:17 pm
Tags:
biotech, biotech stocks, Arrowhead Pharmaceuticals, Arqule, Endocyte, Madrigal Pharmaceuticals
Daiichi Sankyo sweeps out Pieris drug, 5 others in a Q1 pipeline cleanup
Endpoints
Thu, 05/11/17 - 11:41 am
Tags:
Daiichi Sankyo, Pieris, DS-9001, tivantinib, Arqule
Daiichi, ArQule cancer drug fails in late-stage study
BioPharma Dive
Sat, 02/18/17 - 02:43 pm
Tags:
Daiichi Sankyo, Arqule, clinical trials, tivantinib, liver cancer
Battered ArQule shares bump up on badly needed positive data for tivantinib
Fierce Biotech
Mon, 11/10/14 - 11:13 am
Tags:
Arqule, tivantinib, metastatic prostate cancer
ArQule shares rise after committee say liver cancer study can continue with lower drug dose
Yahoo/AP
Fri, 01/17/14 - 08:39 am
Tags:
Arqule, liver cancer, FDA, tivantinib
Data on ArQule's Tivantinib
Yahoo/Zacks
Sat, 10/5/13 - 09:18 am
Tags:
Arqule, tivantinib, Daiichi Sankyo, lung cancer, non-small cell lung cancer
ArQule up on hope for lung cancer drug revival
Reuters
Fri, 09/27/13 - 11:51 am
Tags:
Arqule, tivantinib, Daiichi Sankyo, lung cancer
ArQule to cut liver cancer drug dose on safety concerns
Reuters
Tue, 09/3/13 - 04:20 pm
Tags:
Arqule, liver cancer, tivantinib

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.